79 related articles for article (PubMed ID: 38450950)
21. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
22. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Sun H; Saeedi P; Karuranga S; Pinkepank M; Ogurtsova K; Duncan BB; Stein C; Basit A; Chan JCN; Mbanya JC; Pavkov ME; Ramachandaran A; Wild SH; James S; Herman WH; Zhang P; Bommer C; Kuo S; Boyko EJ; Magliano DJ
Diabetes Res Clin Pract; 2022 Jan; 183():109119. PubMed ID: 34879977
[TBL] [Abstract][Full Text] [Related]
23. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
Evans M; Engberg S; Faurby M; Fernandes JDDR; Hudson P; Polonsky W
Diabetes Obes Metab; 2022 Mar; 24(3):377-390. PubMed ID: 34779107
[TBL] [Abstract][Full Text] [Related]
24. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study.
Vlacho B; Mata-Cases M; Mundet-Tudurí X; Vallès-Callol JA; Real J; Farre M; Cos X; Khunti K; Mauricio D; Franch-Nadal J
Front Endocrinol (Lausanne); 2021; 12():708372. PubMed ID: 34335477
[TBL] [Abstract][Full Text] [Related]
26. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
Page MJ; McKenzie JE; Bossuyt PM; Boutron I; Hoffmann TC; Mulrow CD; Shamseer L; Tetzlaff JM; Akl EA; Brennan SE; Chou R; Glanville J; Grimshaw JM; Hróbjartsson A; Lalu MM; Li T; Loder EW; Mayo-Wilson E; McDonald S; McGuinness LA; Stewart LA; Thomas J; Tricco AC; Welch VA; Whiting P; Moher D
Syst Rev; 2021 Mar; 10(1):89. PubMed ID: 33781348
[No Abstract] [Full Text] [Related]
27. Drug utilisation pattern over 3 years in the real-world treatment of type II diabetes.
Romagnoli A; Santoleri F; Costantini A
Int J Clin Pract; 2021 Jun; 75(6):e14120. PubMed ID: 33655579
[TBL] [Abstract][Full Text] [Related]
28. What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.
Strain WD; Tsang C; Hurst M; McEwan P; Unadkat M; Meadowcroft S; Shardlow R; Evans M
Diabetes Ther; 2020 Jun; 11(6):1381-1395. PubMed ID: 32424798
[TBL] [Abstract][Full Text] [Related]
29. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?
Ma LL; Wang YY; Yang ZH; Huang D; Weng H; Zeng XT
Mil Med Res; 2020 Feb; 7(1):7. PubMed ID: 32111253
[TBL] [Abstract][Full Text] [Related]
30. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Wittmann I; Kempler P
Diabetes Ther; 2018 Oct; 9(5):2133-2141. PubMed ID: 30120754
[TBL] [Abstract][Full Text] [Related]
31. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
[TBL] [Abstract][Full Text] [Related]
32. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study.
Gordon J; McEwan P; Idris I; Evans M; Puelles J
BMJ Open Diabetes Res Care; 2018; 6(1):e000512. PubMed ID: 29755756
[TBL] [Abstract][Full Text] [Related]
33. Association between psychotropic medications and presence of sleep bruxism: A systematic review.
Melo G; Dutra KL; Rodrigues Filho R; Ortega AOL; Porporatti AL; Dick B; Flores-Mir C; De Luca Canto G
J Oral Rehabil; 2018 Jul; 45(7):545-554. PubMed ID: 29663484
[TBL] [Abstract][Full Text] [Related]
34. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.
Harding SD; Sharman JL; Faccenda E; Southan C; Pawson AJ; Ireland S; Gray AJG; Bruce L; Alexander SPH; Anderton S; Bryant C; Davenport AP; Doerig C; Fabbro D; Levi-Schaffer F; Spedding M; Davies JA;
Nucleic Acids Res; 2018 Jan; 46(D1):D1091-D1106. PubMed ID: 29149325
[TBL] [Abstract][Full Text] [Related]
35. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.
McGovern A; Tippu Z; Hinton W; Munro N; Whyte M; de Lusignan S
Diabetes Obes Metab; 2018 Apr; 20(4):1040-1043. PubMed ID: 29135080
[TBL] [Abstract][Full Text] [Related]
36. Rayyan-a web and mobile app for systematic reviews.
Ouzzani M; Hammady H; Fedorowicz Z; Elmagarmid A
Syst Rev; 2016 Dec; 5(1):210. PubMed ID: 27919275
[TBL] [Abstract][Full Text] [Related]
37. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.
Polonsky WH; Henry RR
Patient Prefer Adherence; 2016; 10():1299-307. PubMed ID: 27524885
[TBL] [Abstract][Full Text] [Related]
38. Type 2 diabetes patients' and providers' differing perspectives on medication nonadherence: a qualitative meta-synthesis.
Brundisini F; Vanstone M; Hulan D; DeJean D; Giacomini M
BMC Health Serv Res; 2015 Nov; 15():516. PubMed ID: 26596271
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
[TBL] [Abstract][Full Text] [Related]
40. Adherence to diabetes medication: a systematic review.
Krass I; Schieback P; Dhippayom T
Diabet Med; 2015 Jun; 32(6):725-37. PubMed ID: 25440507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
